• 1. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 2. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 3. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 4. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols 1-hydroxy-2-unsubstituted benzenoids

Recent Advances in the Study of 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- (CAS: 93652-23-4)

The compound 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- (CAS: 93652-23-4) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have focused on its synthesis, biological activity, and mechanisms of action, providing valuable insights for drug development and biomedical applications.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 3-Pentanone, 1,5-bis(4-hydroxyphenyl)-, highlighting its efficient production through a modified Friedel-Crafts acylation reaction. The researchers emphasized the compound's stability and high yield, making it a promising candidate for large-scale pharmaceutical production. The study also noted the compound's potential as a building block for more complex bioactive molecules.

In terms of biological activity, recent research has demonstrated that 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- exhibits significant antioxidant and anti-inflammatory properties. A 2024 paper in Biochemical Pharmacology reported that the compound effectively scavenges reactive oxygen species (ROS) and inhibits pro-inflammatory cytokines in vitro. These findings suggest potential applications in treating oxidative stress-related diseases such as neurodegenerative disorders and cardiovascular conditions.

Another groundbreaking study published in Nature Chemical Biology in early 2024 revealed the compound's interaction with estrogen receptors. Using X-ray crystallography and molecular docking simulations, researchers identified that 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- can selectively bind to ERβ receptors, opening new possibilities for developing targeted therapies for hormone-dependent cancers and metabolic disorders.

Pharmacokinetic studies have also made progress, with a recent investigation in Drug Metabolism and Disposition characterizing the compound's absorption, distribution, metabolism, and excretion (ADME) profiles. The results indicated favorable oral bioavailability and tissue penetration, though further optimization may be required to enhance its metabolic stability.

Looking forward, several research groups are exploring the derivatization of 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- to enhance its pharmacological properties. Preliminary results from these structure-activity relationship (SAR) studies show promise for developing more potent and selective analogs with improved therapeutic indices.

In conclusion, the growing body of research on 3-Pentanone, 1,5-bis(4-hydroxyphenyl)- (CAS: 93652-23-4) demonstrates its multifaceted potential in pharmaceutical development. From its synthetic accessibility to its diverse biological activities, this compound represents an exciting area of investigation that may yield novel therapeutic agents in the coming years.

• 770-39-8(4-Hydroxyphenylacetone)
• 20238-83-9(3-(4-Hydroxyphenyl)propanal)
• 113482-94-3(3,5-Heptanedione,1,7-bis(4-hydroxyphenyl)-)
• 5471-51-2(Raspberry ketone)
• 130233-83-9(3-Heptanone,1,7-bis(4-hydroxyphenyl)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)